Moreover, evaluating combinatorial strategies that integrate GLI1 inhibition with immune checkpoint blockade [34] or that selectively impair self-renewing tumor populations may represent a rational next step in pRCC therapy development. The gene discussed is GLI1; the disease is neoplasm.